KDNY Overview
Upcoming Projects (KDNY)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (KDNY)
-
Delving into the recent phase 3 data from the ALIGN clinical trial of Novartis' atrasentan in patients with IgA Nephropathy.
Tickers: NVS, TVTX, CALT, KDNY
Executed On: Nov 17, 2023 at 09:00 AM EST -
A Third Opinion: Digging into the IgAN landscape with a focus on Travere's Filspari (sparsentan), Calliditas' Nefecon (Tarpeyo/Kinpeygo), and Chinook's Atrasentan
Tickers: CALT, NVS, TVTX, KDNY
Executed On: Jun 13, 2023 at 04:00 PM EDT -
A Second Opinion: Digging into the IgAN landscape with a focus on Travere's Filspari (sparsentan), Calliditas' Nefecon (Tarpeyo/Kinpeygo), and Chinook's Atrasentan
Tickers: CALT, TVTX, KDNY
Executed On: Jun 06, 2023 at 09:00 AM EDT -
Digging into the IgAN landscape with a focus on Travere's Filspari (sparsentan), Calliditas' Nefecon (Tarpeyo/Kinpeygo), and Chinook's Atrasentan
Tickers: CALT, TVTX, KDNY
Executed On: Jun 01, 2023 at 11:30 AM EDT -
A Discussion of ET and APRIL/BAFF targets in IgAN
Tickers: KDNY, TVTX, VERA
Executed On: Jul 26, 2022 at 10:00 AM EDT -
An updated look at Atrasentan and BION-301's potential in treating patients with IgA Nephropathy
Ticker: KDNY
Executed On: Jun 27, 2022 at 03:00 PM EDT
Upcoming & Overdue Catalysts (KDNY)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (KDNY)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
